Ningbo Inno Pharmchem Co., Ltd. is proud to feature the B7-33 peptide, a sophisticated synthetic compound offering advanced solutions for research into fibrotic diseases and beyond. As a trusted supplier of high-quality chemical products, we aim to equip researchers with the most effective tools available.

The B7-33 peptide is a meticulously designed analog of H2 relaxin, a naturally occurring hormone. Its key innovation lies in its selective activation of the Relaxin Family Peptide Receptor 1 (RXFP1). This targeted approach allows B7-33 to primarily engage the pERK signaling pathway, which is instrumental in tissue repair and remodeling. Crucially, it largely bypasses the cAMP pathway, which has been associated with adverse effects like tumor promotion in the case of native relaxin. This makes B7-33 a safer and more precise instrument for scientific exploration.

A primary focus for B7-33 is its role in combating fibrosis, a condition involving excessive scar tissue formation that impairs organ function. Research indicates that B7-33 can effectively reduce fibrotic burden in various organs, including the heart and lungs. This makes it a promising candidate for developing novel treatments for conditions such as cardiac fibrosis and pulmonary fibrosis, where current therapies have limitations. Understanding the B7-33 peptide mechanism of action is key to unlocking its full potential in these areas.

The cardiovascular benefits of B7-33 are also a significant area of interest. Its anti-fibrotic properties can help maintain cardiac integrity, and its potential to improve vascular function adds to its appeal. When comparing B7-33 peptide vs H2 relaxin, B7-33's targeted signaling offers a distinct advantage in terms of safety and efficacy for cardiovascular applications.

The development of B7-33 represents an advancement in peptide synthesis, offering a more streamlined and cost-effective production process compared to natural relaxin. This improved accessibility supports its widespread use in research laboratories. Ningbo Inno Pharmchem Co., Ltd. ensures that our B7-33 peptide meets stringent quality standards, providing researchers with a reliable compound for their critical studies.

Beyond fibrotic and cardiovascular diseases, B7-33 is being explored for its potential in oncology and regenerative medicine. Its unique ability to modulate tissue processes without promoting tumor growth, and its role in tissue repair, open up exciting new avenues for research and development.

The B7-33 peptide is more than just a chemical compound; it is a precision tool for advanced molecular research. Its selective action, demonstrated efficacy, and improved safety profile position it as a vital asset for scientists aiming to develop next-generation therapies. We are proud to support this progress by providing high-quality B7-33 peptide to the research community.